GH Research Ireland Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
GH Research Ireland Limited - overview
Established
2018
Location
Dublin, -, Ireland
Primary Industry
Pharmaceuticals
About
Based in Dublin, Ireland and founded in 2018, GH Research Ireland Limited operates as a pharmaceutical company that focuses on developing therapeutic drugs for psychiatric and neurological disorders. The company's chairman of the board was Florian Schönharting. In April 2021, GH Research Ireland Limited raised USD 125 million in series B funding from Acuta Capital Partners, Boxer Capital, RA Capital, and RTW Investments. The company's line of products includes GH001 is an innovative drug that uses an inhaled formulation of 5-MeO-DMT which helps to treat depression and mental illness.
While GH002 is an injectable formulation of 5-MeO-DMT that focuses on treating mental diseases. GH Research Ireland Limited plans to advance GH001 into clinical development and explore additional drug delivery approaches.
Current Investors
BVF Partners, Verition Fund Management, Deerfield Management
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.ghres.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.